内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

Diabetologia：Empagliflozin在兔糖尿病模型中调节肾交感神经和心率的压力反射？

2020-07-28 MedSci原创 MedSci原创

糖尿病模型
关注

本研究确定empagliflozin是否改变了有意识兔糖尿病模型的肾交感神经活动(RSNA)和压力反射。

本研究确定empagliflozin是否改变了有意识兔糖尿病模型的肾交感神经活动(RSNA)和压力反射。用四氧嘧啶诱发糖尿病，并在有意识的家兔接受empagliflozin、胰岛素、利尿剂乙酰唑胺或ACE抑制剂培哚普利治疗1周前后测量RSNA、平均动脉压(MAP)和心率。

研究结果显示，四氧嘧啶给药四周后，血糖比非糖尿病对照组升高3倍，MAP升高9% (p < 0.05)。与未治疗糖尿病的家兔相比，一周的empagliflozin治疗使血糖稳定下降(−43%)，水摄入量增加(+49%)，但RSNA、MAP或心率没有改变。糖尿病兔的最大RSNA降血压值增加了75% (p < 0.01)，但心率压力反射没有改变。Empagliflozin和乙酰唑胺降低了RSNA压力反射增强(p < 0.05)，与非糖尿病组相似。糖尿病和非糖尿病家兔去甲肾上腺素(去甲肾上腺素)溢出量相似，而empagliflozin和乙酰唑胺处理家兔去甲肾上腺素溢出量要大两倍(p < 0.05)。

研究结果表明，由于empagliflozin可以恢复糖尿病引起的交感反应增强，这可能对糖尿病患者有益。利尿剂乙酰唑胺的类似作用表明，其机制可能涉及增加钠和水的排泄。

原始出处：

Cindy Gueguen, Sandra L. Burke,Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761481, encodeId=87571e6148106, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 11 18:10:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639561, encodeId=e05716395615e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Mar 25 14:10:08 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954278, encodeId=75b419542e8d3, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 13 08:10:08 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043255, encodeId=02651043255af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047835, encodeId=07f7104e835e8, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2021-06-11 ms5439512287675881

    #BET#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1761481, encodeId=87571e6148106, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 11 18:10:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639561, encodeId=e05716395615e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Mar 25 14:10:08 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954278, encodeId=75b419542e8d3, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 13 08:10:08 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043255, encodeId=02651043255af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047835, encodeId=07f7104e835e8, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2021-03-25 ms9608593228839890

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1761481, encodeId=87571e6148106, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 11 18:10:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639561, encodeId=e05716395615e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Mar 25 14:10:08 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954278, encodeId=75b419542e8d3, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 13 08:10:08 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043255, encodeId=02651043255af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047835, encodeId=07f7104e835e8, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2021-07-13 仁医06

    #empagliflozin#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1761481, encodeId=87571e6148106, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 11 18:10:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639561, encodeId=e05716395615e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Mar 25 14:10:08 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954278, encodeId=75b419542e8d3, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 13 08:10:08 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043255, encodeId=02651043255af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047835, encodeId=07f7104e835e8, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-07-28 misszhang

    谢谢MedSci提供最新的资讯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1761481, encodeId=87571e6148106, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Fri Jun 11 18:10:08 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639561, encodeId=e05716395615e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Mar 25 14:10:08 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954278, encodeId=75b419542e8d3, content=<a href='/topic/show?id=ce586e31e6' target=_blank style='color:#2F92EE;'>#empagliflozin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6731, encryptionId=ce586e31e6, topicName=empagliflozin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 13 08:10:08 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1043255, encodeId=02651043255af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047835, encodeId=07f7104e835e8, content=梅斯里提供了很多疾病的模型计算公式，赞一个！, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Jul 28 17:10:08 CST 2020, time=2020-07-28, status=1, ipAttribution=)]
    2020-07-28 CHANGE

    梅斯里提供了很多疾病的模型计算公式，赞一个！

    0